4, 2015 – – Patent expirations on many leading antipsychotic medications could save Medicaid vast amounts of dollars a season as the medications become obtainable in cheaper generic variations, a new study finds. Patients included in Medicaid – – the publicly funded insurance program for the indegent – – account for 70 to 80 % of most antipsychotic prescriptions in the United States, the researchers said. The low costs of ‘second-generation’ antipsychotics, such as for example Abilify and Seroquel, could prompt Medicaid to lift restrictions on usage of the drugs, the scholarly study authors predicted. The drugs are used to treat mental illnesses such as for example schizophrenia and bipolar disorder.Individually, a majority of Allos’ stockholders voted and only the adoption of the Merger Agreement at a special conference of Allos stockholders also kept on October 21, 2011. Related StoriesLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E. KlegermanExpanded use for IntelliCap with further CE Tag for aspiration of liquids The Plank and shareholders of Allos supported the proposed merger with AMAG predicated on the strategic rationale, anticipated working synergies and prospect of future growth of the primary brands.